chufangao/CTO huggingface dataset:
Clinical trial NCT03595618: A Study to Assess Efficacy and Safety of GLPG1972/S201086 in Participants With Knee Osteoarthritis
Official title: Efficacy and Safety of 3 Doses of S201086/GLPG1972 Administered Orally Once Daily in Patients With Knee Osteoarthritis. A 52-week International, Multi-regional, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study
Acronym: Roccella
Sponsor: Galapagos NV (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 932.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-08-14
Primary completion date: 2020-07-14
Completion date: 2020-07-14
Baseline population: Modified Randomised Set (mRS): All included participants to whom a therapeutic unit was randomly assigned using the interactive web response system.
Clinical trial NCT02798471: Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)
Official title: A Phase 3, Open-label, Randomized, Multi-center, Controlled Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of Edoxaban and to Compare the Efficacy and Safety of Edoxaban With Standard of Care Anticoagulant Therapy in Pediatric Subjects From Birth to Less Than 18 Years of Age With Confirmed Venous Thromboembolism (VTE)
Sponsor: Daiichi Sankyo (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 290.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-03-27
Primary completion date: 2022-05-24
Completion date: 2022-05-24
Baseline population: Baseline demographic characteristics were reported in the Randomized Analysis Set.
Plan to share individual participant data: YES
IPD sharing description: De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
IPD time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
IPD access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
Clinical trial NCT03209401: Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies
Official title: Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies
Sponsor: Georgetown University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Lack of accrual
Enrollment: 23.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-10-13
Primary completion date: 2023-10-16
Completion date: 2023-10-16
Plan to share individual participant data: NO
Clinical trial NCT04046848: Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A
Official title: Phase 1/2 Study to Assess the Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Previously Treated Adult Patients With Severe Hemophilia A
Sponsor: Octapharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Study was terminated due to SADRs
Enrollment: 30.0 (ACTUAL)
Number of arms: 5.0
Start date: 2019-07-03
Primary completion date: 2022-02-18
Completion date: 2022-02-18
Clinical trial NCT04972968: A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154
Official title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment
Acronym: AIM-PMR
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Strategic considerations
Enrollment: 181.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-09-09
Primary completion date: 2023-07-24
Completion date: 2023-07-24
Limitations and caveats: AbbVie has decided to discontinue further subject enrollment in the M20-370 (ABBV-154) study. This decision is not based on a safety or an efficacy signal; rather this decision was made because of a change in AbbVie's development.
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
IPD access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Clinical trial NCT03787303: Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma
Official title: A Single Arm Phase II Pilot Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma
Acronym: B-TREUH
Sponsor: Aultman Health Foundation (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Relocation of Principal Investigator
Enrollment: 7.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-03-01
Primary completion date: 2022-03-09
Completion date: 2022-03-09
Limitations and caveats: Limitation is small sample size due to pandemic affecting clinical trial accrual. A larger sample is needed to adequately answer the research question.
Clinical trial NCT03624127: Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis
Official title: A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis
Acronym: POETYK-PSO-1
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 666.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-08-07
Primary completion date: 2020-09-02
Completion date: 2020-09-02
Clinical trial NCT04014361: A Study of LY3154885 in Healthy Participants
Official title: Single- and Multiple-Ascending Dose, Safety, Tolerability, and Pharmacokinetic Study With LY3154885 in Healthy Subjects
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: HUAA study is terminated early due to a business decision.
Enrollment: 36.0 (ACTUAL)
Number of arms: 7.0
Start date: 2019-08-09
Primary completion date: 2020-02-09
Completion date: 2020-02-09
Baseline population: All randomized participants.
Limitations and caveats: A strategic business decision was made to terminate the study prior to initiation of the multiple-ascending dose study (Part C). The secondary objectives pertaining to Part D were not evaluated as the study was terminated before the commencement of Part D.
Plan to share individual participant data: NO
Clinical trial NCT04644315: A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
Official title: A Phase II, Open-Label, Single Arm Decentralized Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
Acronym: ALpha-T
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The data from this study is no longer needed.
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-05-24
Primary completion date: 2022-05-16
Completion date: 2022-05-16
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Clinical trial NCT03966053: The Use of Trifluoperazine in Transfusion Dependent DBA
Official title: Phase I/II, Open Label Study to Determine Safety of Trifluoperazine (TFP) in Adults With Red Blood Cell Transfusion-Dependent Diamond Blackfan Anemia
Acronym: DBA
Sponsor: Northwell Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Supporter terminated study due to slow subject accrual secondary to COVID pandemic limiting travel to research site.
Enrollment: 2.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-09-13
Primary completion date: 2021-10-13
Completion date: 2021-10-13
Limitations and caveats: Protocol closed early due to slow accrual secondary to COVID travel restrictions.
Plan to share individual participant data: NO
Clinical trial NCT05329545: Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)
Official title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants With Recurrent, Platinum-Sensitive, Ovarian Cancer (UP-NEXT)
Acronym: UP-NEXT
Sponsor: Mersana Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Study Terminated by Sponsor
Enrollment: 20.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-06-23
Primary completion date: 2023-09-29
Completion date: 2023-09-29
Plan to share individual participant data: NO
Clinical trial NCT05386368: RECELL to Promote Healing Following Carbon Dioxide (CO2) Laser Treatment in Cosmetic Patients
Official title: Application of RECELL to Promote Healing Following CO2 Laser Treatment in Cosmetic Facelift Patients
Sponsor: Wake Forest University Health Sciences (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention. PI decided to terminate due to slow enrollment.
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-03-22
Primary completion date: 2023-07-07
Completion date: 2024-05-06
Baseline population: We only had one subject total and she received (A) Right receives Recell
Plan to share individual participant data: NO
IPD sharing description: We do not plan on sharing individual participant data with other researchers at this time.
Clinical trial NCT00455039: INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients
Official title: INST 0514C- A Neoadjuvant Phase II Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients: Biologic Correlative Study
Sponsor: University of New Mexico (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: This is a duplicate record and the sponsor has submitted under NCT00206427.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-07-31
Primary completion date: 2023-07-31
Completion date: 2023-07-31
Clinical trial NCT04188431: Dexamethasone and Postoperative Bleeding Following Tonsillectomy in Children
Official title: Dexamethasone and Postoperative Bleeding Following Tonsillectomy in Children: Double-blind, Randomized, Placebo Control, Multi-centre, International, Pragmatic, Non-inferiority Trial
Acronym: Blueberry
Sponsor: University Hospital, Geneva (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Lack of finance
Enrollment: 523.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-01
Primary completion date: 2023-03-30
Completion date: 2024-03-01
Plan to share individual participant data: YES
IPD sharing description: De-identified individual participant data for all primary and secondary outcome measures will be made available
IPD time frame: Up to 2 years following study completion
IPD access criteria: Data access requests from National coordinators or from local investigators will be examined by the steering committee and an agreement will be signed prior to Data access
Clinical trial NCT02539160: Impact of Chronic Kidney Disease on the Effects of Ticagrelor in Patients With Diabetes and Coronary Artery Disease
Official title: Impact of Chronic Kidney Disease on the Pharmacodynamic and Pharmacokinetic Effects of Ticagrelor in Patients With Diabetes Mellitus and Coronary Artery Disease
Sponsor: University of Florida (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 101.0 (ACTUAL)
Number of arms: 4.0
Start date: 2016-02-29
Primary completion date: 2019-11-14
Completion date: 2020-06-17
Baseline population: 77 patients (DM-CKD, n=38; DM-non-CKD, n=39) had pharmacodynamic (PD) data on study drug and represented the PD population that was used for the analysis.
Clinical trial NCT03406780: A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
Official title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Intravenous Delivery of Allogeneic Cardiosphere-Derived Cells in Subjects With Duchenne Muscular Dystrophy
Acronym: HOPE-2
Sponsor: Capricor Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 18.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-03-04
Primary completion date: 2020-03-10
Completion date: 2020-03-10
Plan to share individual participant data: UNDECIDED
Clinical trial NCT05604521: A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI
Official title: A Randomized, Double-blind, Placebo-controlled, Clinical Trial of a 3-dose, 28-day Regimen of PfSPZ Vaccine in Healthy, Adult Participants to Determine Safety, Tolerability and Efficacy Against Heterologous Plasmodium Falciparum Controlled Human Malaria Infection Conducted 3 or 12 Weeks After Immunization
Sponsor: Sanaria Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The main reason for trial discontinuation was the inability to address the primary objectives of the study following an extended gap between the second and third doses.
Enrollment: 60.0 (ACTUAL)
Number of arms: 4.0
Start date: 2022-12-06
Primary completion date: 2023-09-05
Completion date: 2023-09-05
Clinical trial NCT04592861: Carbon Ion RT for Locally Advanced Pancreatic Cancer
Official title: A Prospective, Randomized, Phase 3 Trial of Carbon Ion Radiation Therapy Versus Standard Care for Locally Advanced Pancreatic Cancer
Sponsor: Albert Einstein College of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Study administratively closed out by the Einstein IRB. NO US enrolling sites.
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-01
Primary completion date: 2022-08-24
Completion date: 2022-08-24
Plan to share individual participant data: NO
Clinical trial NCT02593786: A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors
Official title: A Phase 1/2, Open-Label Study of Nivolumab (BMS-936558) in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors (CheckMate 077: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 077)
Acronym: CheckMate 077
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 58.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-01-07
Primary completion date: 2021-09-27
Completion date: 2021-09-27
Clinical trial NCT03507374: PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis
Official title: PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis
Acronym: PINNACLE
Sponsor: University of Utah (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Funding withdrawn
Enrollment: 20.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-10-30
Primary completion date: 2020-04-17
Completion date: 2020-04-17
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04372121: Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain
Official title: A Double-blind Randomized Extension Study to Assess the Long-term Efficacy and Safety of Linzagolix in Subjects With Endometriosis-associated Pain
Acronym: EDELWEISS 5
Sponsor: Kissei Pharmaceutical Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: This study is an extension of Study 18-OBE2109-002 that has been terminated due to enrolment challenges. Consequently, this study has also been terminated.
Enrollment: 30.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-03-23
Primary completion date: 2021-01-08
Completion date: 2021-02-16
Clinical trial NCT04718376: A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer
Official title: A Multicenter, Open-label, Single-arm, Phase Ib Study to Evaluate the Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Platinum-Resistant or Platinum-Refractory Relapsed Ovarian Cancer
Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The sponsor has adjusted its R\&D strategy.
Enrollment: 56.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-01-12
Primary completion date: 2023-05-22
Completion date: 2023-05-22
Plan to share individual participant data: NO
Clinical trial NCT03580616: Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS)
Official title: Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis: A Phase IIa Study
Acronym: ALS
Sponsor: Dartmouth-Hitchcock Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study was terminated by the IRB due to continued noncompliance.
Enrollment: 43.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-10-24
Primary completion date: 2022-08-03
Completion date: 2022-12-20
Clinical trial NCT04209621: Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Official title: Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Due to unexpected sudden death on study.
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-07-31
Primary completion date: 2021-01-22
Completion date: 2021-01-22
Clinical trial NCT05900674: Endovascular Stroke Treatment And Reteplase Protocol
Official title: Endovascular Stroke Treatment And Reteplase Protocol
Acronym: [ESTAR]
Sponsor: Zeenat Qureshi Stroke Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Sponsor
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2023-07-31
Primary completion date: 2024-07-31
Completion date: 2024-07-31
Clinical trial NCT03001349: 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors
Official title: An Expanded Access Imaging of Neuroendocrine Tumors Using 68Ga-DOTA-TOC
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Per PI Request
Enrollment: 4.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-05-16
Primary completion date: 2021-02-05
Completion date: 2021-02-05
Clinical trial NCT03295656: Contrast-Enhanced Ultrasound Diagnosis of Acute Appendicitis
Official title: Contrast-Enhanced Ultrasound Diagnosis of Acute Appendicitis
Sponsor: Boston Children's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Unanticipated delays.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-07-15
Primary completion date: 2020-07-15
Completion date: 2020-07-15
Plan to share individual participant data: NO
Clinical trial NCT04105972: A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del
Official title: A Phase 3b, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del
Sponsor: Vertex Pharmaceuticals Incorporated (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 176.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-03
Primary completion date: 2020-07-24
Completion date: 2020-07-24
Plan to share individual participant data: NO
IPD sharing description: Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent research/clinical-trial-data-sharing.
Clinical trial NCT05150496: Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults in Turkey
Official title: A Phase IIb Randomized Double-Blinded Positive Controlled Trial to Evaluate the Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults Who Have Completed Two Doses of CoronaVac® or the mRNA Vaccine (Comirnaty) in Turkey
Sponsor: Sinovac Biotech Co., Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: SUSPENDED 
Why stopped: The plan has changed
Enrollment: 640.0 (ESTIMATED)
Number of arms: 4.0
Start date: 2022-12-15
Primary completion date: 2023-01-15
Completion date: 2023-01-15
Clinical trial NCT05665088: Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of PRN Dosing of BXCL501 Over a 12 Week Treatment Period in Subjects With Agitation Associated With Dementia
Sponsor: BioXcel Therapeutics Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Study was terminated for business reasons; not due to safety or efficacy concerns
Enrollment: 13.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-12-14
Primary completion date: 2023-09-11
Completion date: 2023-09-11
Plan to share individual participant data: NO